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ABSTRACT

Tumor Necrosis Factor Alpha (TNF-a) is a vital pro-inflammatory cytokine

produced in response to the activation ofthe innate immune response via the Toll-like

receptor signal transduction pathway.

This thesis explores the release and inhibition of

TNF-a from RAW 264.7 mouse macrophages and human U937 cells that have been

exposed to a potent activator of innate immunity.

Using lipopolysaccharide (LPS), a

Gram negative bacterial endotoxin, in the presence or absence of proinflammatory

cytokine interferon 'Y (IFN-y) as activators ofthe TLR-4 pathway, a robust release ofTNF

a was observed.

Co-incubation of stimulated macrophages with the tyrosine

phosphatase inhibitor, sodium vanadate, resulted in a time and concentration

dependent inhibition of stimulated TNF-a release.

These results demonstrate for the

first time that soluble TNF-a release can be inhibited by a small molecule tyrosine

phosphatase inhibitor, and indicates that protein tyrosine phosphorylation is critical to

macrophage TNF-a release.

Since the inappropriate expression of TNF-a occurs in the

pathogenesis of many chronic inflammatory disorders, these results provide a

potentially novel mechanism for regulating macrophage TNF-a release.
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At the extracellular surface,

MD-2 associates with TLR-4 through its leucine-rich repeats (LRR) and binds LPS directly.

Upon ligand stimulation, TLR-4 is oligomerized and an adaptor protein, myeloid

differentiation factor 88 (MyD88), associates with TLR-4 via the intracellular Toll/lL-1

receptor (TIR) domain.

MyD88 possesses two domains: a TIR domain at the (-terminal

end and a death domain at the N-terminal end.

containing protein (TIRAP).

MyD88 also associates with TIR domain

Because TIRAP contains a phosphatidylinositol 4,5-

bisphosphate (PIP2) binding domain, it facilitates MyD88 delivery of the activated TLR-4

to the membrane (Tanimura et al, 2008).

MyD88 then recruits IL-1 receptor-associated kinase 1 (IRAK-1) to TLRs by

interaction of death domains of the two molecules.

This allows the subsequent

association of IRAK-4 which serves to phosphorylate and thus activate IRAK-1.

activated IRAK-1 partners with TNF receptor associated factor 6 (TRAF-6).

Once

The

oligimerization of TRAF-6 activates its ligase activity, leading to polyubiquitination of

target proteins such as TRAF-6 itself (Chen et al, 2008).

This ubiquinated TRAF-6/IRAK-1

complex will then activate TAK-1 binding protein (TAB-1) and TGF-P-activated kinase 1

(TAK-1) (Takeda and Akira, 2004).

TAK-1 and TAB-1 are responsible for triggering IKB

kinase (IKK) and mitogen-activated protein kinase (MAPK) pathways.

These pathways are further broken down into their components.

IKKa, IKKP and

IKKy of the IKK pathway associate with one another to form a complex that is
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responsible for phosphorylating IKB proteins.

IKB proteins serve as inhibitors of the K

light chain gene enhancer in B cells(Lu et al, 2008), which contain a number of copies of

ankyrin repeat sequences which actually mask the nuclear localization signal (NLS) of

NF-KB proteins (Jacobs and Harrison, 1998).

The masking ofthe NLS results in

maintenance of NF-KB proteins in its inactive form and thus the form found sequestered

in the cytoplasm.

Phosphorylation of this inhibitory protein, IKB, leads to its

ubiquitination which then leads to its degradation by proteosomes (Jacobs and Harrison,

1998).

With IKB degraded, the transcription factor, NF-KB, is no longer restricted and

moves into the nucleus where it activates the transcription of pro-inflammatory

cytokines and many other immune associated genes.

LPS exposure also triggers the

MAPK pathway which is activated along with the IKK pathway.

The MAPK pathway also

ultimately leads to the activation of the AP-1 transcription factor which is fundamental

to the expression of pro-inflammatory cytokines such as TNF-a, IL-1� and IL-6 (Trahn-Thi,

1995).

While this complex TLR-4 signal pathway is essential in amplifying the signal

initiated by LPS, numerous levels of regulation exist.

For example, there are protein

inhibitors at the cell surface such as radioprotective 105 (RP105) and MD-2 homolog,

MD-1.

RP105 and MD-1 form a complex that interacts with the TLR-4/MD-2 complex to

directly inhibit its association with LPS (Lu et al, 2008).

Also, once activation has already

begun there are a number of additional negative regulators that serve to regulate the

pathway such as triad domain-containing protein 3 variant A (TRIAD3A) and suppressor
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of cytokine signaling-1 (SOCl-1).

TRIAD3A and SOCl-1 promote the degradation of many

of the key pathway components such as TLR-4 and TIRAP (Lu et al, 2008).

Acting even

further downstream are the negative regulators IL-1 receptor-associated kinase M

(IRAK-M)and A20.

Previous studies suggest that despite its name IRAK-M lacks kinase

activity and works in inhibitory manner by preventing the dissociation of MyD88 from

IRAKs (Wesche et al, 1999).

A20 is an enzyme the de-ubiquinates thereby removing

ubiquitin moieties from TRAF-6 (Lu et al, 2008).

As noted earlier, the non-ubiquinated

form ofTRAF-6 will not be able to complex with IRAK-1 to recruit TAB-1 and TAK-1 thus

terminating the downstream signaling events (Figure 1).

While protein kinases are known activators of macrophages TNF-a release, the

role of protein phosphatases, which regulate kinase function, remains unclear.

Analogous to protein kinases, protein phosphatases

fall into three general categories:

serine/threonine phosphatases, tyrosine phosphatases and dual specificity

threonine/tyrosine phosphatases (Barford, 2002)

Protein phosphatases are generally

categorized by functional inhibitors, for example while serine/threonine phosphatases

are differentially inhibited by natural products, such as okadaic acid, tyrosine

phosphatases can be inhibited by a range of

products such as small molecules and

synthetic chemical compounds (reviewed in Heneberg, 2009).

Protein tyrosine

phosphatase (PTP) inhibition leads to an up-regulation of kinase activity (Hooft van

Huisduijnen et al, 2002).

In the current study, we examine the effects of a broad

spectrum tyrosine phosphatase inhibitor, sodium vanadate, on endotoxin stimulated

4

macrophage responses.

We find that sodium vanadate inhibits macrophage TNF-a

release in a concentration and time-dependent manner.

Our results provide the first

experimental evidence that tyrosine phosphatases are critically involved in TNF-a

release.

5

...
'

m

----

JL-1JJ

TNFa

IL-6

RANTES

IL•12

MIP1a

n-e

MIPlP,

"-.. tnftammation

Figure 1. Toll-Like Receptor (TLR) Pothwoy.

The modified image demonstrates the LPS

activated TLR-4 pathway, illustrating adaptor proteins, kinases, transcription factors and
cytokines produced during an inflammatory response. Modified from lnvitrogen Corporation.
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MATERIALS AND METHODS

Cell Culture

The human leukemic monocyte lymphoma cell line (U937) was obtained from

American Type Culture Collection (ATCC; Manassas, VA) and maintained with Roswell

Park Memorial Institute (RPMI) growth medium (lnvitrogen; Carlsbad, CA) plus 10% fetal

bovine serum and 1% penicillin/streptomycin.

Cells were grown at 37"C in a humidified

2

atmosphere in the presence of 5% C02•

Cells were maintained in T-75 cm flasks and 24-

well cell culture dishes (Corning; Corning, NY).

The mouse macrophage cell line, RAW

264.7, was obtained from the ATCC and was propagated in culture as described (Dos

2

Santos et al, 2007).

RAW 264.7 cells were maintained in 100 mm

culture dishes in

RPMI medium with 5% fetal calf serum in a humidified atmosphere with 5% C02•

solutions and plastic-ware were cell culture grade, endotoxin free.

passaged at 70% confluence and split 1:10 (dish:dish ratio).

Cells were routinely

Cells used in experiments

are allowed to recover for 48 hours prior to experimentation.
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All

Enzyme Linked lmmunosorbent Assay

Soluble TNF-a levels were quantified using a commercially available enzyme

linked immunosorbent assay (ELISA) kit (Biolegend; San Diego, CA).

U937 and RAW

264. 7 cells were cultured separately in 24-well cell culture plates (Corning; Corning, NY)

at a density of 40,000 cells/ml for 48 hours or until 90-100% confluency was achieved.

After this incubation period, cell were washed with Dulbecco's Phosphate Buffered

Saline (DPBS) (Sigma-Aldrich; St. Louis, MO ) and treated with Opti-MEM, a serum-free

cell culture media {lnvitrogen; Carlsbad, CA) .

After 12-18 hours of incubation with Opti-MEM, the media was removed and the

cells were treated with lipopolysaccharide (LPS), interferon gamma (IFN- y) and sodium

vanadate.

One control and six experimental groups were used (Table 1).

The cells were

treated with 10 µg/ml LPS {lnvitrogen; Carlsbad, CA) in the presence or absence of

lOng/ml IFN-y (Sigma-Aldrich; St. Louis, MO).

TNF-a inhibition experiments were

carried out in the presence of 100 µM sodium vanadate (Sigma-Aldrich; St. Louis, MO ).

The treated cells were incubated at 37"C and the supernatants were collected after 2

hours.

For time courses the same steps were taken up until sample collection.

Instead,

samples were collected at O minutes, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2

hours, 4 hours and 6 hours.

Each sample was frozen at -80°C upon collection before

assay.
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Cell supernatant samples were then thawed on ice to avoid TNF-a degradation.

Once the samples were thawed, there were analyzed using ELISA MAX™ Deluxe Sets to

quantify levels of soluble TNF-a.

One day prior to running the ELISA, depending on the

cell type being analyzed, human or mouse TNF-a capture antibody is added to the NUNC

Maxisorp 96 Micro Well Plates and left to incubate at 4 "C overnight.

washed 4 times with 300 µL wash buffer and blotted dry each time.

The plate was then

Because the

capture antibody does not cover the surface of the high-affinity binding plate in its

entirety, there are spaces left empty where protein may attach and in turn, cause a false

reading.

In order to block non-specific binding to these empty spaces, 200 µL of assay

diluent was added to each well and allowed to incubate for one hour at room

temperature.

The assay diluent contains proteins that will attach to the surface of the

plate thereby minimizing non-specific interaction of other proteins such as the antigen

to the surface of the plate.

The blocking step was then followed by four washings.

Next 100 µL of each sample was loaded into each well.

A TNF-a standard curve

was generated for each ELISA plate and all treatments were performed in triplicate.

The

standard curve was made up of the following TNF-a concentrations: 500 pg/ml, 250

pg/ml, 125 pg/ml, 62.5 pg/ml, 31.3 pg/ml, 15.6 pg/ml, 7.8 pg/ml and O pg/ml.

sample dilutions were carried out with assay diluents.

All

Loading of the samples into the

wells was followed by a 2 hour incubation period at room temperature with gentle

shaking.

After, the plate was washed once again four times with wash buffer, and then

treated with 100 µL ofTNF-a detection antibody.
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+

y
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Table 1. Treatments used far ELISA. The U937 and RAW 264.7 cells were treated in the above
manner.

Cells were treated with 10 µg/ml LPS, 10 ng/ml

vanadate.

Stock solutions were diluted in Opti-MEM.
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IFN-

y

and 100 µM sodium

Statistical Analysis

All results were calculated and presented as the mean ± SEM for each control or

treatment group.

Statistical comparisons between the means of different groups were

performed by multiple ANOVA with a Neuman-Keuls multiple comparison post-

test.

Statistical comparisons and analysis were performed with GraphPad Prism 4 and

statistical significance was defined as p<0.05.
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RESULTS

Soluble TNF-a Secretion

TNF-a is a critical pro-inflammatory cytokine.

In our studies, U937 and

RAW264.7 cells were used as a monocyte model system to assess the effects of LPS, IFN

y, and sodium vanadate on soluble TNF-a levels which were stimulate by the Gram

negative bacterial endotoxin, LPS.

LPS activates a robust and sustained TNF-a response

in our cell models, thereby making these cells a valuable model for studying pro

inflammatory cytokine release (Guha and Mackman, 2000).

Untreated U937 cells

demonstrated basal release ofTNF-a at a level of 105 pg/ml (see Fig 1).

Treatment of

U937 cells with 10 µg/ml LPS increased TNF-a levels to 560 pg/ml translating into an

increase by 455

±

40 pg/ml from basal (see Fig 2, **p<0.001 basal versus LPS treated).

Treatment with lOng/ml IFN-y stimulated the release of TNF-a to 375 pg/ml thus

increasing by 270

±

55 pg/ml from basal (see Fig 2, *p<0.01 basal versus IFN-y treated).

When cells were treated with both LPS and IFN-y together 515 pg/ml TNF-a was

released increasing by 410

treated).

levels.

± 35

pg/ml (see Fig 2, **p<0.001 basal versus LPS + IFN-y

All three of these experimental groups caused a significant increase in TNF-a

On the other hand, treatment of U937 cells with sodium vanadate, a broad

spectrum protein tyrosine phosphatase inhibitor, left TNF-a levels at 108 pg/ml, a value

very close to that of basal levels.

Sodium vanadate suppressed LPS stimulated TNF-a

from 560 pg/ml to 130 pg/ml when cells were treated with LPS in the presence of

13

sodium vanadate.

Similarly, when cells are treated with IFN-y and LPS in the presence of

sodium vanadate there is a decrease to 185 pg/ml TNF-u from the 375 pg/ml seen with

cells treated with I F N - y alone (see Fig 2).
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Figure 2.

ELISA reveals levels of soluble TNF-a secretion from U937 cells.

U937 cells

were treated with [10 µg/ml] LPS and [10 ng/ml] IFN-y in the presence or absence of
[lOOµM] Na3V04. Cell supernatants were collected after 2 hours of incubation and
soluble TNF-a quantified by ELISA.

Data are means +SEM from two independent

experiments, each performed in triplicate.
with Newman-Keuls post hoc test.

Data were analyzed by multiple ANOVA

Using GraphPad Prism statistical significance was

defined as p<0.05. *p<0.01; **p<0.001. L: LPS; N: Na 3 V0 4; g: IFN-y.
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Quantifying TNF-a release from RAW 264.7 cells in response to lPS

+/-

IFN-y

resulted in similar effects as those observed with U937 cells, although we noted a

substantial difference in the total amount of TNF-a released (see Fig 3).

TNF-a in RAW 264.7 is 442 pg/ml.

Basal release of

There is an increase from basal levels to 26,200

pg/ml TNF-a observed when RAW 264.7 cells are treated with 10 µg/ml lPS (an

increase by 25,800

±

3,100 pg/ml from basal) and an increase to 20,600 pg/ml when

treated with 10 ng/ml IFN-y (an increase by 20,200

±

1,500 pg/ml from basal).

lPS and

IFN-y together increase TNF-a levels to 31,000 pg/ml TNF-a (an increase by 30,600

5,000 pg/ml from basal).

±

Cells treated with sodium van ad ate alone have levels of TNF-a

that remain in the range of basal release; in this case, 528 pg/ml.

Once cells are treated

with sodium vanadate in the presence of lPS and/or IFN-y there is an inhibition of TNF-a

release.

When RAW 264.7

cells are treated with lPS in the presence of sodium

vanadate TNF-a levels drop to 4,040 pg/ml.

Similarly, when cells are treated with lPS

and IFN-y in the presence of sodium vanadate TNF-a level drop again to 4,020 pg/ml

(see Fig 3).
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Figure 3.

ELISA reveals levels of soluble TNF-a secretion from RA W264.7 cells.

RAW

264.7 cells were treated with [100 µm] Na3V04, [10 µg/ml] LPS, and [10 ng/ml] IFN-y.
Cell supernatants were collected after 2 hours of incubation and soluble TNF-a
quantified by ELISA.
triplicate.

Results are the mean from a single experiment performed in

LPS and I F N - y induced TNF- a release was decreased from cells treated

with Na3V04.

L: LPS; N: Na 3 V0 4 ; g: IFN-y.
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Time Course of TNF-a Secretion

The TLR signal transduction pathway of the innate i m m u n e response elicits a sequential

pro-inflammatory cytokine response.

In U937 cells, basal levels of TNF-a increases

approximately three-fold over a 6 hour time course ranging from 68 pg/ml at O minutes

to 210 pg/ml at 360 minutes increasing by 142

±

16 pg/ml from O minutes (see Fig 4).

LPS treated U937 cells exhibited an elevated time-dependent increase in TNF-a levels

increasing from 187 pg/ml at O minutes to 1,580 pg/ml at 360 minutes (see Fig 4; an

increase by 1390

±

13 pg/ml from O minutes).

IFN--y treated cells also demonstrated in

increase in TNF-a over time, elevating from 120 pg/ml at O minutes to 1,230 pg/ml at

360 minutes (see Fig 4; an increase by 1110

± 25

pg/ml from O minutes).

Again, when

cells were treated with both LPS and IFN--y an increase in TNF-a is seen over time; levels

increase from 137 pg/ml at O minutes to 1,170 pg/ml (see Fig 4; an increase by 1,000

33 pg/ml at O minutes).

±

However, cells treated with sodium vanadate showed no

significant increase in TNF-a throughout the 6 hour period.

Cells treated with LPS in the

presence of sodium vanadate demonstrated a sustained inhibition of TNF-a over time

ranging from 120 pg/ml at O minutes to 140 pg/ml at 360 minutes.

Similarly cells

treated with both LPS and IFN--y in the presence of sodium vanadate exhibited a

sustained suppression ofTNF-a release ranging from 120 pg/ml at O minutes and 130

pg/ml at 360 minutes (see Fig 4).
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Figure 4.

Time course of soluble TNF- a release from U937 cells.

The results

demonstrate a time-dependent increase in LPS and IFN-y TNF- a release. Na3V04
blocked TNF-a release from these cells.

The results shown are the mean+/- SEM for

three experiments, each performed in triplicate.
ANOVA with a Newman-Keuls post hoc test.
*p<0.05.

L: LPS; N: NaN04; g: IFN-y.
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Data were analyzed by multiple

Statistical significance was defined as

DISCUSSION

The introduction of foreign pathogens into the body elicits an immediate innate

immune response and triggers an array of immune cells to synthesize critical

inflammatory mediators and cytokines.

The release of cytokines is fundamental for

intercellular communication in the immune response.

Despite being essential in acute

inflammation, chronic expression of certain pro-inflammatory cytokines are an

underlying cause for numerous chronic inflammatory and autoimmune disorders.

For

this reason, understanding the signal transduction and trafficking pathways of cytokines

such as TNF-u and IFN-y is a vital area of study.

Activation of the TLR signal transduction pathway initiates an intracellular kinase

cascade that leads to the activation of transcription factors responsible for producing

inflammatory cytokines such as TNF- n,

Protein kinases are crucial to cytokine release

and when these enzymes are selectively activated they serve to enable this pathway.

LPS, a potent Gram negative bacterial endotoxin specifically triggers the TLR-4 pathway

leading to an activation of a protein kinase cascade that ultimately up-regulates the

transcription ofTNF-u (Aderem and Ulevitch, 2000) by NF-KB.

In our studies we demonstrate that LPS and IFN-y stimulate the release of

soluble TNF-u from both a h u m a n monocyte cell line, U937 cell, and a mouse monocyte

20

cell line, RAW 264.7 cells.

Monocytic responses to LPS are well documented (Guha and

Mackman, 2001) and the cellular events that culminate in TNF-a release are well known

(see Fig 1).

Although monocytes also have molecular components that suppress the TLR

pathway, the availability of a small molecule chemical inhibitor of TLR-induced TNF-a

release could prove invaluable for experimental studies.

Small molecule inhibitors are

known to exist, but these act predominately through the elevation of intracellular cyclic

nucleotide levels (Essayan, 1999) or through transcriptional suppression of cytokine

genes (Gupta et al, 2010).

A pathway inhibitor that affects protein phosphatase activity

has not been explored.

In this thesis, we demonstrate

that the treatment of cells with the pro

inflammatory mediators, LPS and IFN-y in the presence of sodium vanadate inhibits

stimulated TNF-a levels.

Based upon our knowledge of protein tyrosine phosphatase

inhibitors, such as sodium vanadate, an inhibitor would suppress the effects of

phosphatases thereby enabling kinases.

Because we are studying a kinase enabled

pathway, the treatment of cells with a phosphatase inhibitor would be thought to lead

to an up-regulation of the transcriptional products.

However, what we observe from

the ELISA results shown above is that there is an extreme inhibition in soluble TNF-a

levels when treated with LPS and LPS+IFN-y in the presence of sodium vanadate in

contrast with LPS or LPS+IFN-y alone.
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Although the mechanisms for sodium vanadate 's actions have not yet been

established, numerous potential molecular targets exist.

The TLR-4 signaling pathway is

a tightly regulated cycle employing negative regulators such as IRAK-M, RP105 and A20

to shut off the pathway once the signal is no longer needed (Kobayashi et al, 2002).

One

speculation is that sodium vanadate may be acting to up-regulate negative regulators

such as those listed above.

Such an up-regulation would lead to an inhibition of the

players involved in activating NFKb.

NFKb is the transcription factor responsible for

producing TNF-u therefore and inhibition of NFKb will lead to an inhibition of TNF-a

production.

TNF-a is an early response cytokine that acts in the recruitment and activation of

additional immune cells to the site of invasion.

Because the ELISA is measuring soluble

TNF-a, there is a possibility that sodium vanadate may not be interfering with the TLR-4

signaling pathway but rather acting at a post-transcriptional level.

Once transcription is

achieved in the nucleus, its products, such as TNF-a, must still follow a trafficking

pathway before they can be secreted out of the cell to carry out cell to cell

communication.

Newly transcribed TNF-a move from the nucleus to the Golgi complex

and from golgi complex to the recycling endosomes where it finally moves out towards

the phagocytic cup (Figure 5).

Once the TNF-a is at the phagocytic cup the ectodomain

is cleaved by TNF-u converting enzyme (TACE) resulting in a now soluble cytokine that is

released by the cell (Stow et al, 2009).

If sodium vanadate acts as a TACE inhibitor,

soluble TNF-a will not be formed and will not be secreted by the cell.
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If sodium

vanadate is indeed a TACE inhibitor it may serve as another explanation for the

decreased levels of TNF-a shown by the above ELISA quantifications.

The simplistic route ofTNF-a movement described above involves many

different proteins such as adaptors, coat proteins, lipids, small GTPases and golgins to

succeed in efficient trafficking of cytokines.

One of the key proteins involved are

members of the soluble N-ethylmaleimide-sensitive factor attachment protein receptors

{SNARE) family of membrane fusion proteins.

In general, Q-SNAREs complex with R

SNAREs on opposing membranes to allow for fusion of vesicles carrying cytokines such

as TNF-a.

In immune cells the specific components of the abovementioned SNAREs

responsible for forming the complexes have been identified as syntaxin4 and SNAP23

from the Q-SNARE family and VAMPS, VAMP7 and VAMP2 from the R-SNARE family

{Stow et al, 2009).

These SNARE proteins are involved in every step of the way from the

Golgi to the recycling endosome and from the endosome to the cell surface.

For this

reason the levels and concentrations of SNARE proteins have a direct effect on the

volume and efficiency of cytokine trafficking.

Previous studies have shown that siRNA

knockdown of VAMP3, an R-SNARE protein involved in TNF-a trafficking, led to a

reduced secretion of cytokines (Manderson et al, 2007).

Therefore, sodium vanadate

interference with the formation of SNARE complexes can serve as an explanation for

decreased levels of soluble TNF-a.
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Whatever the molecular target may be, because the presence of sodium

vanadate has a sustained inhibitory effect on soluble TNF-a that remains unchanged

over time, it may serve as a treatment for chronic inflammatory and autoimmune

disorders.

Current treatments include protein biologics that use monoclonal antibodies

specific for TNF-a to remove already secreted TNF-a.

However, the treatment of cells

with sodium vanadate proposes a way to treat these conditions by preventing elevated

levels of TNF-a before it is even released from the cell.
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Figure 5.
release.
complex.

TNF-a trafficking and secretion in macrophages.

Once TNF-a leaves the endoplasmic reticulum, it is transported in the Golgi
From the Golgi, TNF-a is packaged into vesicles to move the cytokine into the

recycling endosome and out

a

Proposed model for TNF-a

to the surface of the cell, with the dominant release of TN F

occurring at the phagosome.

Taken from Stow et al. Cytokine secretion in

macrophages and other cells: pathways and mediators. lmmunobiology 214: 601612 (2009).
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CONCLUSION

In this study, we reveal the stimulatory effects of LPS and IFN-y on soluble TNF-u

levels in mouse and human monocyte cell lines, U937 and RAW 264.7.

We have

demonstrated that the presence of sodium vanadate in combination with the

aforementioned stimulants is responsible for an inhibitory effect on soluble TNF- u

levels.

Although LPS and IFN-y are causing a time dependent increase of TNF- u, once

cells are treated with LPS and IFN-y in the presence of sodium vanadatethere is a

sustained inhibition ofTNF- u.

The use of two different cell lines has allowed us to make

the conclusion that the effects are conserved across at least two different species.

This novel inhibitory effect of sodium vanadate on the cells of the immune

system may lead to the development oftherapeutic agents used to control chronic

inflammatory and autoimmune disorders.

must first be uncovered.

In order for this to occur, a molecular target

Potential molecular mechanisms/targets proposed include an

up-regulation of negative regulators in the TLR signaling pathway, interruption in the

formation of SNARE complexes, and mimicry of an inhibitor of TACE.
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